AbbVie faces questions about Skyrizi competition from J&J

April 29, 2026 02:52 PM EDT Pharma As Ab­b­Vie posts more strong Skyrizi sales, Wall Street frets over J&J pill Max Gelman Senior Editor Threats to Ab­b­Vie’s im­munol­o­gy dom­i­nance took cen­ter stage on the com­pa­ny’s first-quar­ter earn­ings call Wednes­day morn­ing, as an­a­lysts pressed ex­ec­u­tives on their de­fense strat­e­gy. The … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER